SEMA-AP

1. Current or < 2 week use of another GLP1-receptor agonist

2. Less than 2 weeks use of any anti-hyperglycemic agent other than insulin

3. Planned or ongoing pregnancy

4. Breastfeeding individuals

5. Severe hypoglycemic episode within the last 3 months, defined as an event where glucose was < 4 mmol/L resulting in seizure, loss of consciousness, or need to present to the emergency department

6. Severe diabetic ketoacidosis (DKA) within the last 6 months ("severe" referring to need to present to medical attention and requirement of intravenous insulin)

7. Prior history of acute pancreatitis, chronic pancreatitis, or gallbladder disease

8. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

9. Severe impairment of renal function with eGFR <15 mL/min/1.73 m2 (using CKD-EPI formula), measured within the last 12 months

10. Clinically significant diabetic retinopathy or gastroparesis, as per the clinical judgment of the investigator

11. History of bariatric surgery within 6 months of screening

12. Any serious medical or psychiatric illness likely to interfere with study participation as per the judgment of the investigator (e.g. cirrhosis, active cancer, decompensated schizophrenia)

13. Prior adverse reaction to GLP1-RAs

14. Body mass index ≤ 21 kg/m2

15. Regular use of hydroxyurea during the expected time of Dexcom G6 use, as this medication is known to cause inaccurate measurements (43)

16. Failure to comply to the study protocol and/or research group's recommendations (e.g. change in pump parameters, ketone measurement)

17. Inability or unwillingness to comply to safe diabetes management in the view of the study group (e.g. inappropriate treatment of hypoglycemia or lack thereof)

18. Any demonstrate of difficulty in using the iMAP system following training, as per investigator's judgment

19. Concern for safety of the participant, as per the clinical judgment of the primary investigator

**Note that for reasons of medicolegal protection for medical supervision, participants must be Canadian residents.**